Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA test could make psychiatric meds safer for kids

NCT ID NCT04797364

Knowledge-focused Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a simple saliva test can help doctors choose the right psychiatric medications for children and teens aged 6 to 24. The test looks at the child's DNA to predict how they might respond to different drugs. Researchers hope this will lead to fewer side effects and better symptom control. The study involves 6,000 participants across four Canadian provinces.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pharmacogenetic testing (saliva-based DNA analysis)
What this could lead to
If successful, this could show that genetic testing helps reduce side effects and improve treatment for young people with mental health conditions.
What could go wrong
This is an observational study, not a treatment trial. It may not prove that genetic testing directly improves outcomes, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 24 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Medical records available * The initiation, change, dose adjustment, or augmentation of psychiatric medication(s) is indicated * Treating psychiatrist, family physician, or pediatrician licensed in Alberta, British Columbia, Saskatchewan, or Manitoba requests pharmacogenetic testing Exclusion Criteria: * Medically unstable or lacking capacity to provided informed consent * Unwillingness of child to provide saliva sample for genetic analysis * History of liver or bone marrow (hematopoietic cell) transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mental health impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder bipolar disorder Depression mental disorder Psychological Well-Being Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mental health impairment

Contacts and locations

Locations

  • University of Calgary

    Calgary, Alberta, T2N 4N1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.